A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
← catalyst calendarNCT07455851 · readout in 2,598 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
150estimated
Sites
6
Countries
Australia, Greece
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-26 | actual | When the study began enrolling |
| Primary completion | 2033-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
- Drug: Linvoseltamab — also filed as Lynozyfic™, REGN5458
- Drug: REGN17372+Linvoseltamab
Primary outcomes
what the primary-completion date above is the date OFOccurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamab
measured Up to 35 days
Occurrence of Treatment Emergent Adverse Events (TEAEs) associated with REGN17372 in combination with linvoseltamab
measured Up to 5 years
Severity of TEAEs associated with REGN17372 in combination with linvoseltamab
measured Up to 5 years
Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination study drugs
measured Within 12 weeks of starting cycle 1
VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapy
measured Within 12 weeks of starting cycle 1
Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination study drugs
measured Within 12 weeks of starting cycle 1
PR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapy
measured Within 12 weeks of starting cycle 1
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed